Regulus Therapeutics Inc (NASDAQ: RGLS) kicked off on Tuesday, remained unchanged from the previous trading day, before settling in for the closing price of $1.75. Over the past 52 weeks, RGLS has traded in a range of $0.83-$2.91.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -10.71% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -42.89%. With a float of $53.18 million, this company’s outstanding shares have now reached $65.50 million.
In an organization with 34 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Regulus Therapeutics Inc (RGLS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Regulus Therapeutics Inc is 19.71%, while institutional ownership is 63.69%. The most recent insider transaction that took place on Jan 30 ’25, was worth 54,260. In this transaction Chief Executive Officer of this company bought 50,000 shares at a rate of $1.09, taking the stock ownership to the 260,808 shares. Before that another transaction happened on Jan 30 ’25, when Company’s Director bought 19,610 for $1.06, making the entire transaction worth $20,787. This insider now owns 22,169 shares in total.
Regulus Therapeutics Inc (RGLS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -42.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 40.21% growth over the previous five years of trading.
Regulus Therapeutics Inc (NASDAQ: RGLS) Trading Performance Indicators
Take a look at Regulus Therapeutics Inc’s (RGLS) current performance indicators. Last quarter, stock had a quick ratio of 10.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.88, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Regulus Therapeutics Inc (RGLS)
Let’s dig in a bit further. During the last 5-days, its volume was 8.01 million. That was better than the volume of 1.11 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 60.68%. Additionally, its Average True Range was 0.18.
During the past 100 days, Regulus Therapeutics Inc’s (RGLS) raw stochastic average was set at 75.41%, which indicates a significant increase from 61.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 112.90% in the past 14 days, which was higher than the 85.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3094, while its 200-day Moving Average is $1.5496. However, in the short run, Regulus Therapeutics Inc’s stock first resistance to watch stands at $1.9767. Second resistance stands at $2.2033. The third major resistance level sits at $2.3567. If the price goes on to break the first support level at $1.5967, it is likely to go to the next support level at $1.4433. The third support level lies at $1.2167 if the price breaches the second support level.
Regulus Therapeutics Inc (NASDAQ: RGLS) Key Stats
The company with the Market Capitalisation of 115.93 million has total of 66,243K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -46,360 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -12,790 K.
